ViiV’s Potential HIV Blockbuster Among Latest Drugs To Win EMA Nod
A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.
You may also be interested in...
Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.
A first EU approval for Ultomiris added to a label expansion for Soliris in the US made for a good seven days for Alexion’s C5 product portfolio.
The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.